Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease: The Emerging Role of VDAC

Alpha-Synuclein (αSyn) is a protein whose function is still debated, as well as its role in modulation of mitochondrial function in both physiological and pathological conditions. Mitochondrial porins or Voltage-Dependent Anion Channel (VDAC) proteins are the main gates for ADP/ATP and various subst...

Full description

Bibliographic Details
Published in:	Biomolecules
Main Authors:	Pierpaolo Risiglione, Federica Zinghirino, Maria Carmela Di Rosa, Andrea Magrì, Angela Messina
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Subjects:	Alpha-Synuclein mitochondria VDAC Parkinson’s disease mitochondrial dysfunction
Online Access:	https://www.mdpi.com/2218-273X/11/5/718

Similar Items

Changes in Drp1 Function and Mitochondrial Morphology Are Associated with the α-Synuclein Pathology in a Transgenic Mouse Model of Parkinson’s Disease
by: Philipp Portz, et al.
Published: (2021-04-01)

Recombinant yeast VDAC2: a comparison of electrophysiological features with the native form
by: Andrea Magrì, et al.
Published: (2019-07-01)

PARK Genes Link Mitochondrial Dysfunction and Alpha-Synuclein Pathology in Sporadic Parkinson’s Disease
by: Wen Li, et al.
Published: (2021-07-01)

Alpha Synuclein Toxicity and Non-Motor Parkinson’s
by: Gabriella M. Mazzotta, et al.
Published: (2024-07-01)

Alpha-Synuclein Aggregation in Parkinson's Disease
by: E. Srinivasan, et al.
Published: (2021-10-01)

Interactions of alpha-synuclein with membranes in Parkinson's disease: Mechanisms and therapeutic strategies
by: Baoyi Li, et al.
Published: (2024-10-01)

Metformin-Induced Apoptosis Is Mediated Through Mitochondrial VDAC1
by: Anna Shteinfer-Kuzmine, et al.
Published: (2025-05-01)

Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease
by: Demetrius M. Maraganore
Published: (2011-05-01)

Interaction between Neuromelanin and Alpha-Synuclein in Parkinson’s Disease
by: Shengli Xu, et al.
Published: (2015-06-01)

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease
by: Fanni F. Geibl, et al.
Published: (2024-10-01)

The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models
by: Rachel Kelly, et al.
Published: (2021-11-01)

Alpha-synuclein inclusions reduced by PIKfyve inhibition in Parkinson disease cell models
by: Sara Lucas-Del-Pozo, et al.
Published: (2025-10-01)

Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson’s Disease
by: Maria Angela Samis Zella, et al.
Published: (2019-01-01)

Editorial: Biomarkers and Pathogenesis of Alpha-Synuclein in Parkinson's Disease
by: Puyu Li, et al.
Published: (2021-10-01)

New Perspectives on Roles of Alpha-Synuclein in Parkinson’s Disease
by: Guoxin Zhang, et al.
Published: (2018-11-01)

Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson’s patients
by: Laura de Boni, et al.
Published: (2024-06-01)

Association between Serum Alpha-Synuclein Levels and Parkinson's Disease Stage
by: Yuliarni Syafrita, et al.
Published: (2022-08-01)

Non-Overlapping Distributions and Functions of the VDAC Family in Ciliogenesis
by: Shubhra Majumder, et al.
Published: (2015-07-01)

The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease
by: Alice J. White, et al.
Published: (2018-11-01)

Alpha-Synuclein Effects on Mitochondrial Quality Control in Parkinson’s Disease
by: Lydia Shen, et al.
Published: (2024-12-01)

Silencing the Mitochondrial Gatekeeper VDAC1 as a Potential Treatment for Bladder Cancer
by: Belal Alhozeel, et al.
Published: (2024-04-01)

Decoding Cancer through Silencing the Mitochondrial Gatekeeper VDAC1
by: Tasleem Arif, et al.
Published: (2024-10-01)

Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease
by: Scott G. Allen, et al.
Published: (2023-11-01)

Thoracic trauma promotes alpha-Synuclein oligomerization in murine Parkinson's disease
by: Wolfgang P. Ruf, et al.
Published: (2022-11-01)

In Silico Exploration of Alternative Conformational States of VDAC
by: Carmen Mannella
Published: (2023-04-01)

VDAC1-Based Peptides as Potential Modulators of VDAC1 Interactions with Its Partners and as a Therapeutic for Cancer, NASH, and Diabetes
by: Anna Shteinfer-Kuzmine, et al.
Published: (2024-09-01)

Neuropathological stages of neuronal, astrocytic and oligodendrocytic alpha-synuclein pathology in Parkinson’s disease
by: Maria Otero-Jimenez, et al.
Published: (2025-02-01)

Alpha-Synuclein and the Endolysosomal System in Parkinson’s Disease: Guilty by Association
by: Maxime Teixeira, et al.
Published: (2021-09-01)

Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes
by: Gabriel Gustafsson, et al.
Published: (2017-12-01)

Alpha-synuclein is increased in erythrocytes in parkinson’s disease cases
by: Ryan N. Coyle, et al.
Published: (2025-08-01)

Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor Hallmarks
by: Swaroop Kumar Pandey, et al.
Published: (2022-06-01)

Alpha-Synuclein and Cognitive Decline in Parkinson Disease
by: Tian-Sin Fan, et al.
Published: (2021-11-01)

Binding of α-synuclein to ACO2 promotes progressive mitochondrial dysfunction in Parkinson's disease models
by: Jie Jiao, et al.
Published: (2024-11-01)

Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
by: Martin T. Henrich, et al.
Published: (2023-11-01)

Dysfunctional mitochondria uphold calpain activation: Contribution to Parkinson's disease pathology
by: A. Raquel Esteves, et al.
Published: (2010-03-01)

Alpha-synuclein overexpression does not cause vocalization deficits in a mouse model of parkinsonism
by: Brooke Rodgers, et al.
Published: (2025-09-01)

Erythrocytic alpha-synuclein as potential biomarker for the differentiation between essential tremor and Parkinson’s disease
by: Zhenwei Yu, et al.
Published: (2023-08-01)

The Impact of <i>SNCA</i> Variations and Its Product Alpha-Synuclein on Non-Motor Features of Parkinson’s Disease
by: Luca Magistrelli, et al.
Published: (2021-08-01)

VDAC2-mediated regulation of calcium homeostasis in cardiomyocytes (a review)
by: N. V. Schcetinina, et al.
Published: (2020-12-01)

Alpha-Synuclein and LRRK2 in Synaptic Autophagy: Linking Early Dysfunction to Late-Stage Pathology in Parkinson’s Disease
by: Giulia Lamonaca, et al.
Published: (2020-04-01)